Biotech Values

[mcbio]

Bearish signal? The point of MNTA management is to maximize shareholder value and if they can obtain $20+/share today for its mLovenox revenue stream they would be foolish not too even if they have 99% certainty tLovenox will never obtain approval, IMHO.

Yes, the point is to maximize shareholder value. So, the question in my mind is does MNTA management view monetization of its generic Lovenox profits as greater than the profits it can earn by retaining its rights to generic Lovenox profits over the longer term if it has confidence that m-enoxaparin will remain the sole generic Lovenox. FWIW, I am not strictly saying that MNTA's potential decision to monetize its generic Lovenox profits means it's not confident that it will remain the sole company with generic Lovenox approval. If management views the decision to monetize generic Lovenox profits as the greatest way to maximize shareholder value, even if they are confident they will remain the only company with generic Lovenox approval, presumably they will do so. I am simply questioning whether or not the monetization of the generic Lovenox profits is the best way to maximize shareholder value.

Now if NVS is willing to pay $1 billion for mLovenox I would hope CW could negotiate selling all of MNTA for $2+ billion.

FWIW, I'm fine with a buyout north of $2B. ; )